Pharming Group PHGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.74
- Day Range
- €0.74–0.74
- 52-Week Range
- —–1.62
- Bid/Ask
- €0.73 / €0.74
- Market Cap
- €495.31 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.27
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 382
- Website
- https://www.pharming.com
Comparables
Valuation
Metric
|
PHGN
|
MRUS
|
PHVS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.62 | 9.50 | 2.60 |
Price/Sales | 2.27 | 80.46 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PHGN
MRUS
PHVS
Financial Strength
Metric
|
PHGN
|
MRUS
|
PHVS
|
---|---|---|---|
Quick Ratio | 1.16 | 5.07 | 20.11 |
Current Ratio | 1.43 | 5.23 | 20.53 |
Interest Coverage | −2.66 | — | — |
Quick Ratio
PHGN
MRUS
PHVS
Profitability
Metric
|
PHGN
|
MRUS
|
PHVS
|
---|---|---|---|
Return on Assets (Normalized) | −3.79% | −30.56% | −29.37% |
Return on Equity (Normalized) | −8.05% | −41.70% | −31.42% |
Return on Invested Capital (Normalized) | −4.58% | −44.08% | −32.27% |
Return on Assets
PHGN
MRUS
PHVS
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Vertex Pharmaceuticals Inc
VRTX
| Gqbdjfrw | Ywpjm | $124.1 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Bklsdpyg | Rtgbf | $114.2 Bil | |||
Moderna Inc
MRNA
| Zcvmpylj | Wrh | $53.7 Bil | |||
argenx SE ADR
ARGX
| Rkrrjcw | Kth | $23.0 Bil | |||
BioNTech SE ADR
BNTX
| Ymjxdtmt | Htgmw | $22.2 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Hdxrbqcy | Dklmhsz | $20.3 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Dgykdcxf | Jrljb | $15.9 Bil | |||
United Therapeutics Corp
UTHR
| Vfjskbjcc | Sdk | $12.8 Bil | |||
Incyte Corp
INCY
| Jsfqwzsd | Kdxqf | $12.2 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Cwjrcdbhnz | Bqzfgk | $12.2 Bil |